Tomohiro Fukuda

Tomohiro Fukuda

Auto-generated profile, based on publicly available information

Tomohiro Fukuda

Department of Gastroenterology Yokohama Municipal Citizen's Hospital Kanagawa Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2019 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TFTomohiro Fukuda
Tomohiro Fukuda
MNMakoto Naganuma
Makoto Naganuma
TKTakanori Kanai
Takanori Kanai
Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto- severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.

30 January 2020 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SMShinta Mizuno
Shinta Mizuno
KOKeiko Ono
Keiko Ono
YMYohei Mikami
Yohei Mikami
MNMakoto Naganuma
Makoto Naganuma
TFTomohiro Fukuda
Tomohiro Fukuda
TKTakanori Kanai
Takanori Kanai
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota. We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC. Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05). In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.

25 February 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SSShintaro Sagami
Shintaro Sagami
TKTaku Kobayashi
Taku Kobayashi
KAKanako Aihara
Kanako Aihara
MUMisaki Umeda
Misaki Umeda
KOKazuhiro Odajima
Kazuhiro Odajima
THToshifumi Hibi
Toshifumi Hibi

6 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TFTomohiro Fukuda
Tomohiro Fukuda
MNMakoto Naganuma
Makoto Naganuma
SSShinya Sugimoto
Shinya Sugimoto
KNKosaku Nanki
Kosaku Nanki
SMShinta Mizuno
Shinta Mizuno
TKTakanori Kanai
Takanori Kanai
5-Aminosalicylic acids (5-ASA) are effective for ulcerative colitis (UC) as a maintenance therapy. It is not clear when and how to reduce a dose of 5-ASA after inducing remission. We aimed to investigate the clinical characteristics and evaluate the risk factors of relapse for UC patients receiving 5-ASA. The medical records of prospectively registered UC patients who received oral 5-ASA as maintenance therapy between January and December 31, 2014, were investigated. The patients’ clinical characteristics in a 2-year follow-up were compared between a relapse group and a remission group. Of 527 UC patients receiving only oral 5-ASA, 390 (74.0%) maintained remission and 137 (26.0%) relapsed during the follow-up period. Multivariable analysis indicated that a shorter duration of disease remission (p < 0.001, OR: 1.24, 95% CI: 1.12–1.38) was statistically significant for each comparison between the remission and relapse groups among all the patients. Risk factors for clinical relapse were a shorter duration of disease remission (p <0.001, OR: 1.17, 95% CI: 1.04–1.33) in the high-dose 5-ASA group and a shorter duration of disease remission (p = 0.003, OR: 1.45, 95% CI: 1.13–1.89) and a history of steroid use (p = 0.048, OR: 4.73, 95% CI: 1.01–22.2) in the low-dose group. A dose reduction of 5-ASA might be cautiously selected in UC patients with a history of steroid use and a shorter duration of disease remission.

1 September 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MMMakoto Mutaguchi
Makoto Mutaguchi
MNMakoto Naganuma
Makoto Naganuma
SSShinya Sugimoto
Shinya Sugimoto
TFTomohiro Fukuda
Tomohiro Fukuda
KNKosaku Nanki
Kosaku Nanki
TKTakanori Kanai
Takanori Kanai

11 March 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SOShinji Okabayashi
Shinji Okabayashi
HYHajime Yamazaki
Hajime Yamazaki
KTKeiichi Tominaga
Keiichi Tominaga
MMMiki Miura
Miki Miura
SSShintaro Sagami
Shintaro Sagami
IGIBD Terakoya Group
IBD Terakoya Group